Journey Medical's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Journey Medical (DERM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Journey Medical vs Its Competitors
- TTM: Trailing 12-month revenue of 68M vs 599,940M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+8.6% annualized vs trailing 12 months), vs accelerating (+2.4%) for its tracked peer group.
- Growth: Journey Medical generated 23.3% revenue growth year over year in Q2 2026, vs 12.4% for its competitors combined.
- Profitability: Its -1.7% net margin compares with 6.3% for the peer group.
- Scale: Journey Medical ranks #269 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Journey Medical accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $1.18M compares with $1.04M for the peer group (1.1x).
- Structure: Journey Medical operates in the following segments: Dermatological segment.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
DERM Sales vs. its Competitors, Q2 2026
Journey Medical reported revenue growth of 23.33 % year on year in Q2 2026, above its competitors' combined revenue growth of 12.44 %.
With a net margin of -1.69 %, Journey Medical reported lower profitability than its competitors (6.33 %).
Journey Medical generated 0.01 % of the combined sales of its peer group, up from 0.01 % a year earlier.
API endpoints for this dataset
Journey Medical vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Journey Medical reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Journey Medical and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Journey Medical Corp | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Journey Medical's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 23.3% for Journey Medical. Journey Medical's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Journey Medical's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Journey Medical Corp | No | Yes | Yes | No |
| Competitors combined (188) | ||||
| High-Confidence Competitors (1) | - | |||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 50.00 % (4 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
DERM Stock Performance relative to its Competitors
DERM Stock Performance relative to High-Confidence Competitors
DERM Stock Performance relative to Similar-Size Competitors
DERM Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Gt Biopharma Inc | 282.9% | Outperformed |
| 2 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 3 | Spyre Therapeutics Inc | 282.9% | Outperformed |
| 4 | Gossamer Bio Inc | 282.9% | Outperformed |
| 5 | Damora Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Journey Medical's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Journey Medical's Comment on Competition and Industry Peers
Publicly Traded Peers of Journey Medical Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Journey Medical Corp |
122.90 | 68.18 |
 Eli Lilly And Company |
1,209,663.60 | 86,462.00 |
 Akari Therapeutics Plc |
875,251.06 | - |
 Johnson and Johnson |
676,352.29 | 99,335.00 |
 Beone Medicines Ltd |
612,622.08 | 6,128.24 |
 Abbvie Inc |
516,201.32 | 66,014.00 |
| SUBTOTAL | 6,492,560.17 | 843,171.25 |
Sign in to see all competitors of Journey Medical Corp.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Journey Medical Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Journey Medical's Competitors Named by the Company
Competitive relationships identified from Journey Medical reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Dermira Inc. | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Novan Inc | Company report | 85% |
| Arcutis Biotherapeutics Inc | Company report | 85% |
| Verrica Pharmaceuticals Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Revance Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Journey Medical's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Journey Medical's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Journey Medical Corp | Dermatological segment 100.00 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Journey Medical Corp.
Journey Medical's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Journey Medical Corp | 123 | 1,175,534 | -105,241 |
| Eli Lilly And Company | 1,209,664 | 1,729,240 | 551,594 |
| Akari Therapeutics Plc | 875,251 | - | -4,674,667 |
| Johnson and Johnson | 676,352 | 705,504 | 114,311 |
| Beone Medicines Ltd | 612,622 | 510,686 | 54,642 |
| Abbvie Inc | 516,201 | 1,158,140 | 181,509 |
| PEERS TOTAL | 6,492,437 | 1,035,377 | 146,333 |
Sign in to see all peers for Journey Medical Corp.
Journey Medical's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 54.39 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Journey Medical Corp.
Journey Medical's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Journey Medical's industry classification, broader than the peer set above. Market cap in millions of $.Journey Medical ranks #269 of 495 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 269 | Journey Medical Corp | 123 | 0.00 % |
Market cap and industry share for the rest of Journey Medical's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Journey Medical's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 264 | Proqr Therapeutics N v | 142 | -42.92 % |
| 265 | Foghorn Therapeutics Inc | 132 | -52.75 % |
| 266 | Nkarta Inc | 129 | -13.33 % |
| 267 | Scienture Holdings Inc | 124 | 314.54 % |
| 268 | Emmis Acquisition Corp | 1,234 | 12.3% |
| 269 | Journey Medical Corp | 123 | -49.43 % |
| 270 | Zentalis Pharmaceuticals Inc | 1,234 | 12.3% |
| 271 | Cue Biopharma Inc | 1,234 | 12.3% |
| 272 | Adagene Inc | 1,234 | 12.3% |
| 273 | Semnur Pharmaceuticals Inc | 1,234 | 12.3% |
| 274 | Lexaria Bioscience Corp | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Journey Medical's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Journey Medical's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 65.45 % | 37.89 % (avg) | +27.6 pp |
| Operating Margin | -4.41 % | industry median | -3.7 pp |
| EBITDA Margin | 0.63 % | -6.23 % (avg) | +6.9 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 7.58 % (avg) | -7.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Journey Medical's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | 370.7x | 15.9x | +354.7x |
| P/B | 5.2x | 4.3x | +0.9x |
| Return on Equity | -20.23 % | industry aggregate | -36.58 % |
| Return on Invested Capital | -3.59 % | -9.83 % (avg) | 6.24 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Journey Medical's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | - | 500.00 % | 41.90 % | 16.69 % | 7.48 % | -29.11 % | 10.20 % |
| Operating Margin | -6,613.65 % | -505.40 % | -55.25 % | -37.35 % | -2.62 % | -24.36 % | -13.21 % |
| Return on Invested Capital | -37.24 % | -49.50 % | -14.49 % | -34.41 % | -6.85 % | -28.84 % | -11.41 % |
| P/E | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Journey Medical's Strategic Group Map
Journey Medical is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Journey Medical's trailing-12-month revenue growth of 20.9% and operating margin of -4.4% compares with an average of 18.9% growth and -2.8% margin across its 8 closest peers by combined growth, margin and ROIC -- Journey Medical sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Journey Medical's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Journey Medical falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Journey Medical's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Journey Medical's dedicated Suppliers and Customers pages, not here.
Journey Medical's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Journey Medical falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Journey Medical's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+8.6% annualized vs trailing 12 months).
Weaknesses
- Return on equity 36.6 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of competitors (46.40 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Journey Medical's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Journey Medical Corp | 0.63 | 1.62 | 0.89 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Akari Therapeutics Plc | 0.23 | 0.26 | 0.04 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.19 | 0.79 | - |
Sign in to see all peers for Journey Medical Corp.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Journey Medical's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Journey Medical Corp | Q2 2026 | +23.3 % | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| PEERS TOTAL | +9.8 % | +12.5 % |
Sign in to see all peers for Journey Medical Corp.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Journey Medical's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Journey Medical Corp | Q2 2026 | +24.4 % | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
Sign in to see all peers for Journey Medical Corp.
Journey Medical's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Journey Medical Corp | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Akari Therapeutics Plc | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 7.48% | 12.87% | - |
Sign in to see all peers for Journey Medical Corp.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Journey Medical's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Journey Medical Corp | - | 1.80 |
| Eli Lilly And Company | 43.96 | 13.99 |
| Akari Therapeutics Plc | - | - |
| Johnson and Johnson | 41.79 | 6.81 |
| Beone Medicines Ltd | 924.91 | 99.97 |
| Abbvie Inc | 50.14 | 7.82 |
| PEERS AVERAGE | 54.49 | 7.70 |
Sign in to see all peers for Journey Medical Corp.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.